Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Astellas to Spend Another Y40bn on Buybacks This Fiscal Year (Japan)

This article was originally published in PharmAsia News

Executive Summary

Astellas Pharma Inc. reports it will spend as much as 40 billion yen to buy back up to 8 million of its own shares, or about 1.54 percent of those outstanding, this fiscal year. The drugmaker has ample cash on hand, and is facing a pressing need to manage its assets more efficiently. The plan means that Astellas will have bought more than 16 million of its own shares in the current fiscal year ending March 2008. Its treasury stock would surpass 20 million, or approximately 4 percent of outstanding shares. The company's policy is to keep treasury stock at around 1 percent to 2 percent of outstanding shares, so it will probably retire more than 10 million shares, possibly next year. The firm's shareholders have been demanding that it use its funds more efficiently. (Click here for more - May Require Paid Subscription

You may also be interested in...

EWG Study Suggests More Than One In 10 Talc-Based Cosmetics Contain Asbestos

The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.

Atlas Biomed Unlocking Japan’s OTC Market With Direct-To-Consumer DNA And Microbiome Tests

Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus. 

Hair Supplement Linked To Cases Of Severe Hepatitis In France

France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts